Advances in the treatment of virus-induced asthma

Expert Review of Respiratory Medicine

Volumn 10, Issue 6, 2016, Pages 629-641

  Tay, Hock ^a,b   Wark, Peter A B ^a,b,c   Bartlett, Nathan W ^a,b,d  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

airway inflammation; bronchoconstriction; corticosteroids; cytokine; epithelium; innateanti viral immunity; monoclonal antibody; Rhinovirus; type 2 immunity; agonists

Indexed keywords

ALPHA INTERFERON; ANTI RHINOVIRUS COMPOUND; ANTIVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN E ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1 MONOCLONAL ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; RHINOVIRUS VACCINE; THEOPHYLLINE; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIVIRAL THERAPY; ASTHMA; DISEASE EXACERBATION; EPITHELIUM CELL; HUMAN; IMMUNITY; NONHUMAN; PERSONALIZED MEDICINE; PROTEIN TARGETING; REVIEW; RHINOVIRUS; TYPE 2 IMMUNITY; ACUTE DISEASE; COMPLICATION; VIROLOGY; VIRUS DISEASES;

ACUTE DISEASE; ASTHMA; HUMANS; VIRUS DISEASES;

EID: 84965058511     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2016.1180249     Document Type: Review

References (133)

1. Global Initiative for Asthma. From the global strategy for asthma management and prevention. 2015. Available from: http://www.ginasthma.org/.
2. K.B.Weiss, S.D.Sullivan The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107(1):3–8.
3. A.Custovic, S.L.Johnston, I.Pavord, et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68(12):1520–1531.
4. G.B.Marks, P.K.Correll, M.Williamson. Asthma in Australia 2005. Med J Aust. 2005;183(9):445–446.
5. T.Haahtela, M.Järvinen, T.Kava, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325(6):388–392.
6. P.J.Barnes. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245–254.
7. F.M.Ducharme, M.Ni Chroinin, I.Greenstone, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;4:CD005533.
8. R.A.Pauwels, C.G.Löfdahl, D.S.Postma, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405–1411.
9. M.Tamm, D.H.Richards, B.Beghé, et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012;106(Suppl 1):S9–19.
10. M.R.Edwards, M.W.Johnson, S.L.Johnston. Combination therapy: synergistic suppression of virus induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol. 2006;34:616–624.
11. K.R.Chapman, N.C.Barnes, A.P.Greening, et al. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010;65(8):747–752.
12. I.J.Doull, F.C.Lampe, S.Smith, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ. 1997;315(7112):858–862.
13. K.Rueter, J.Bizzintino, A.C.Martin, et al. Symptomatic viral infection is associated with impaired response to treatment in children with acute asthma. J Pediatr. 2012;160(1):82–87.
14. C.L.Skevaki, I.Christodoulou, I.S.Spyridaki, et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy. 2009;39(11):1700–1710.
15. N.W.Bartlett, L.Slater, N.Glanville, et al. Defining critical roles for NF-kappaB p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol Med. 2012;4(12):1244–1260.
16. B.J.Thomas, R.A.Porritt, P.J.Hertzog, et al. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep. 2014;4:7176.
17. J.M.Davies, M.L.Carroll, H.Li, et al. Budesonide and formoterol reduce early innate anti-viral immune responses in vitro. PLoS One. 2011;6(11):e27898.
18. B.J.Lipworth. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–955.
19. H.W.Kelly, A.L.Sternberg, R.Lescher, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904–912.
20. M.V.Aun, M.R.Ribeiro, C.L.Costa Garcia, et al. Esophageal candidiasis–an adverse effect of inhaled corticosteroids therapy. J Asthma. 2009;46(4):399–401.
21. L.L.Reber, F.Daubeuf, M.Plantinga, et al. A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol. 2012;188(7):3478–3487.
22. T.M.Laidlaw, J.A.Boyce. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy. 2012;42(9):1313–1320.
23. R.Palmantier, H.Rocheleau, M.Laviolette, et al. Characteristics of leukotriene biosynthesis by human granulocytes in presence of plasma. Biochim Biophys Acta. 1998;1389(3):187–196.
24. S.D.Message, V.Laza-Stanca, P.Mallia, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105(36):13562–13567.
25. M.L.Seymour, N.Gilby, P.G.Bardin, et al. Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects. J Infect Dis. 2002;185(4):540–544.
26. C.E.Heise, B.F.O’Dowd, D.J.Figueroa, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275(39):30531–30536.
27. C.A.CamargoJr, D.M.Gurner, H.A.Smithline, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol. 2010;125(2):374–380.
28. S.A.Antoniu. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets. 2014;18(11):1285–1292.
29. F.Novelli, L.Malagrinò, F.L.Dente, et al. Efficacy of anticholinergic drugs in asthma. Expert Rev Respir Med. 2012;6(3):309–319.
30. B.J.Proskocil, H.S.Sekhon, Y.Jia, et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology. 2004;145(5):2498–2506.
31. L.E.Kistemaker, P.S.Hiemstra, I.S.Bos, et al. Tiotropium attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells. Thorax. 2015;70(7):668–676.
32. G.J.Rodrigo, J.A.Castro-Rodriguez. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60(9):740–746.
33. B.Griffiths, F.M.Ducharme. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013;8:CD000060.
34. H.A.Kerstjens, B.Disse, W.Schroder-Babo, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308–314.
35. C.Vogelmeier, B.Hederer, T.Glaab, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
36. H.A.Kerstjens, M.Engel, R.Dahl, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
37. K.M.Kew, D.J.Evans, D.E.Allison, et al. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;6:CD011438.
38. L.M.Graham, N.Eid. The impact of asthma exacerbations and preventive strategies. Curr Med Res Opin. 2015;31:1–11.
39. H.BinMahfouz, B.Borthakur, D.Yan, et al. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting beta2-adrenoceptor agonist-induced gene expression in human airway epithelial cells. Mol Pharmacol. 2015;87(1):64–76.
40. B.G.Cosío, B.Mann, K.Ito, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med. 2004;170(2):141–147.
41. P.Celis, G.Rada. High-dose inhaled corticosteroids or addition of theophylline in patients with poorly controlled asthma? Medwave. 2015;15(Suppl 2):e6224.
42. S.W.Turner, T.Heaton, J.Rowe, et al. Early-onset atopy is associated with enhanced lymphocyte cytokine responses in 11-year-old children. Clin Exp Allergy. 2007;37(3):371–380.
43. P.D.Sly, A.L.Boner, B.Björksten, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet. 2008;372(9643):1100–1106.
44. P.G.Woodruff, B.Modrek, D.F.Choy, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–395.• Identified a Th2-high gene signature in the bronchial epithelium of approximately 50% of adult asthmatics identifying a sub-population that could respond to type-2 immune-targeting therapies.
45. H.Spits, D.Artis, M.Colonna, et al. Innate lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145–149.
46. J.L.Barlow, A.Bellosi, C.S.Hardman, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol. 2012;129(1):191-198.e4.
47. K.R.Bartemes, G.M.Kephart, S.J.Fox, et al. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol. 2014;134(3):671–678.e4.
48. R.M.Green, A.Custovic, G.Sanderson, et al. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ. 2002;324(7344):763.
49. C.S.Murray, G.Poletti, T.Kebadze, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax. 2006;61(5):376–382.
50. D.J.Jackson, H.Makrinioti, B.M.Rana, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014;190(12):1373–1282.•• Used the human experimental RV infection model and direct sampling techniques to show that type-2 cytokines are increased during an asthma exacerbation and are related to IL-33 expression and disease severity.
51. D.W.MacGlashanJr, B.S.Bochner, D.C.Adelman, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158(3):1438–1445.
52. S.Walker, M.Monteil, K.Phelan, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;2:CD003559.
53. W.W.Busse, W.J.Morgan, P.J.Gergen, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015.
54. S.J.Teach, M.A.Gill, A.Togias, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485.
55. J.T.Schroeder, A.P.Bieneman, H.Xiao, et al. TLR9- and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol. 2005;175(9):5724–5731.
56. M.A.Gill, G.Bajwa, T.A.George, et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol. 2010;184(11):5999–6006.
57. S.R.Durrani, D.J.Montville, A.S.Pratt, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012;130(2):489–495.• This study showed that pDC from children have impaired anti-viral immunity to RV that was associated with FcεRI expression and crosslinking providing evidence that treatment with anti-IgE has the potential to block allergic reactions and promote anti-viral immunity.
58. G.G.Brusselle, J.C.Kips, J.H.Tavernier, et al. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy. 1994;24(1):73–80.
59. T.K.Hart, M.N.Blackburn, M.Brigham-Burke, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130(1):93–100.
60. J.W.Steinke. Anti-interleukin-4 therapy. Immunol Allergy Clin North Am. 2004;24(4):599–614, vi.
61. A.J.Coyle, G.Le Gros, C.Bertrand, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 1995;13(1):54–59.
62. E.Piper, C.Brightling, R.Niven, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338.
63. N.A.Hanania, M.Noonan, J.Corren, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–756.
64. S.Wenzel, L.Ford, D.Pearlman, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
65. M.Contoli, K.Ito, A.Padovani, et al. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy. 2015;70(8):910–920.
66. J.Beale, A.Jayaraman, D.J.Jackson, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014;6(256):256ra134.•• Employed studies in both human in vitro primary bronchial epithelial cells and mouse models to show that IL-25 is a key regulator of RV-induced activation of type-2 immunity and allergic airways disease thereby providing evidence to support it as a target for therapy.
67. A.Jatakanon, S.Lim, P.J.Barnes. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000;161(1):64–72.
68. H.G.Ortega, M.C.Liu, I.D.Pavord, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
69. E.H.Bel, S.E.Wenzel, P.J.Thompson, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.•• This human clinical trial showed treatment of patients with severe eosinophilic asthma with a mAb targeting IL-5 (mepolizumab) reduced the dose of ICS required to maintain asthma control and reduced the number of exacerbations.
70. M.Castro, S.E.Wenzel, E.R.Bleecker, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890.
71. D.J.Fraenkel, P.G.Bardin, G.Sanderson, et al. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med. 1995;151(3 Pt 1):879–886.
72. I.Mahmutovic-Persson, H.Akbarshahi, N.W.Bartlett, et al. Inhaled dsRNA and rhinovirus evoke neutrophilic exacerbation and lung expression of thymic stromal lymphopoietin in allergic mice with established experimental asthma. Allergy. 2014;69(3):348–358.
73. I.D.Pavord, S.Korn, P.Howarth, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
74. S.J.Ballantyne, J.L.Barlow, H.E.Jolin, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2007;120(6):1324–1331.
75. Y.H.Wang, P.Angkasekwinai, N.Lu, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007;204(8):1837–1847.
76. D.R.Neill, S.H.Wong, A.Bellosi, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–1370.
77. Y.J.Chang, H.Y.Kim, L.A.Albacker, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631–638.
78. S.Ying, B.O’Connor, J.Ratoff, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol. 2005;174(12):8183–8190.
79. B.Zhou, M.R.Comeau, T.De Smedt, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6(10):1047–1053.
80. G.M.Gauvreau, P.M.O’Byrne, L.P.Boulet, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110.
81. R.F.LemanskeJr. The childhood origins of asthma (COAST) study. Pediatr Allergy Immunol. 2002;13(Suppl 15):38–43.
82. D.J.Jackson, R.E.Gangnon, M.D.Evans, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178(7):667–672.
83. M.Starkhammar, O.Larsson, S.KumlienGeorén. Toll-like receptor ligands LPS and poly (I:C) exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation. PLoS One. 2014;9(8):e104114.
84. V.Hornung, S.Rothenfusser, S.Britsch, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531–4537.
85. I.Ioannidis, F.Ye, B.McNally, et al. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol. 2013;87(6):3261–3270.
86. S.Møller-Larsen, M.Nyegaard, A.Haagerup, et al. Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax. 2008;63(12):1064–1069.
87. M.Roponen, S.T.Yerkovich, E.Hollams, et al. Toll-like receptor 7 function is reduced in adolescents with asthma. Eur Respir J. 2010;35(1):64–71.
88. J.Moisan, P.Camateros, T.Thuraisingam, et al. TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol. 2006;290(5):L987–95.
89. L.Hatchwell, A.Collison, J.Girkin, et al. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia. Thorax. 2015;70(9):854–861.
90. P.Camateros, M.Tamaoka, M.Hassan, et al. Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am J Respir Crit Care Med. 2007;175(12):1241–1249.
91. M.G.Drake, G.D.Scott, B.J.Proskocil, et al. Toll-like receptor 7 rapidly relaxes human airways. Am J Respir Crit Care Med. 2013;188(6):664–672.
92. D.Tsitoura, C.Ambery, M.Price, et al. Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015;98(4):369–380.
93. C.M.Greene, N.G.McElvaney. Toll-like receptor expression and function in airway epithelial cells. Arch Immunol Ther Exp (Warsz). 2005;53(5):418–427.
94. E.Juarez, C.Nunez, E.Sada, et al. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res. 2010;11:2.
95. B.Koller, R.Bals, D.Roos, et al. Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest. 2009;39(7):535–547.
96. J.N.Kline, T.J.Waldschmidt, T.R.Businga, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998;160(6):2555–2559.
97. V.V.Jain, K.Kitagaki, T.Businga, et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol. 2002;110(6):867–872.
98. E.C.Borden, G.C.Sen, G.Uze, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975–990.
99. A.K.Perry, G.Chen, D.Zheng, et al. The host type I interferon response to viral and bacterial infections. Cell Res. 2005;15(6):407–422.
100. J.W.Schoggins. Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol. 2014;6:40–46.
101. P.A.Wark, S.L.Johnston, F.Bucchieri, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–947.
102. M.R.Edwards, N.Regamey, M.Vareille, et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 2013;6(4):797–806.
103. V.Gielen, A.Sykes, J.Zhu, et al. Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. J Allergy Clin Immunol. 2015;136(1):177–188e11.
104. S.V.Kotenko, G.Gallagher, V.V.Baurin, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77.
105. M.Contoli, S.D.Message, V.Laza-Stanca, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026.
106. O.Koltsida, M.Hausding, A.Stavropoulos, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med. 2011;3(6):348–361.
107. C.U.Duerr, C.D.McCarthy, B.C.Mindt, et al. Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat Immunol. 2016;17(1):65–75.
108. K.Moro, H.Kabata, M.Tanabe, et al. Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat Immunol. 2016;17:76–86.
109. N.Lopez-Souza, S.Favoreto, H.Wong, et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol. 2009;123(6):1384–1390.e2.
110. Y.A.Bochkov, K.M.Hanson, S.Keles, et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 2010;3(1):69–80.
111. E.K.Miller, J.Z.Hernandez, V.Wimmenauer, et al. A mechanistic role for type III IFN-lambda1 in asthma exacerbations mediated by human rhinoviruses. Am J Respir Crit Care Med. 2012;185(5):508–516.
112. A.Sykes, M.R.Edwards, J.Macintyre, et al. TLR3, TLR4 and TLRs7–9 induced interferons are not impaired in airway and blood cells in well controlled asthma. PLoS One. 2013;8(6):e65921.
113. R.Djukanovic, T.Harrison, S.L.Johnston, et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014;190(2):145–154.
114. S.L.Johnston, P.K.Pattemore, G.Sanderson, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310(6989):1225–1229.
115. S.L.Johnston, P.K.Pattemore, G.Sanderson, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med. 1996;154(3 Pt 1):654–660.
116. T.V.Grissell, H.Powell, D.R.Shafren, et al. Interleukin-10 gene expression in acute virus-induced asthma. Am J Respir Crit Care Med. 2005;172(4):433–439.
117. J.M.Greve, G.Davis, A.M.Meyer, et al. The major human rhinovirus receptor is ICAM-1. Cell. 1989;56(5):839–847.
118. S.Traub, A.Nikonova, A.Carruthers, et al. An anti-human icam-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLoS Pathog. 2013;9(8):e1003520.
119. R.B.Couch. The common cold: control? J Infect Dis. 1984;150(2):167–173.
120. M.R.Edwards, T.Kebadze, M.W.Johnson, et al. New treatment regimes for virus-induced exacerbations of asthma. Pulm Pharmacol Ther. 2006;19(5):320–334.
121. F.G.Hayden, T.Coats, K.Kim, et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antivir Ther. 2002;7(1):53–65.
122. A.K.Patick, S.L.Binford, M.A.Brothers, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43(10):2444–2450.
123. G.Lu, J.Qi, Z.Chen, et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;85(19):10319–10331.
124. P.Mastromarino, D.Capobianco, F.Cannata, et al. Resveratrol inhibits rhinovirus replication and expression of inflammatory mediators in nasal epithelia. Antiviral Res. 2015;123:15–21.
125. B.N.Sadarani, A.S.Majumdar. Resveratrol potentiates the effect of dexamethasone in rat model of acute lung inflammation. Int Immunopharmacol. 2015;28(1):773–779.
126. A.C.Palmenberg, J.E.Gern. Classification and evolution of human rhinoviruses. Methods Mol Biol. 2015;1221:1–10.
127. K.Niespodziana, K.Napora, C.Cabauatan, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. Faseb J. 2012;26(3):1001–1008.
128. N.Bartlett, S.Johnston. Rhinoviruses. In: B.Mahy, M.Regenmortel, editors. Encyclopedia of virology. 3rd ed. Oxford: Elsevier; 2008. p. 467–475.
129. J.Iwasaki, W.A.Smith, S.R.Stone, et al. Species-specific and cross-reactive IgG1 antibody binding to viral capsid protein 1 (VP1) antigens of human rhinovirus species A, B and C. PLoS One. 2013;8(8):e70552.
130. J.Edlmayr, K.Niespodziana, T.Popow-Kraupp, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J. 2011;37(1):44–52.
131. M.K.Cooney, J.A.Wise, G.E.Kenny, et al. Broad antigenic relationships among rhinovirus serotypes revealed by cross-immunization of rabbits with different serotypes. J Immunol. 1975;114(2 Pt 1):635–639.
132. N.W.Bartlett, R.P.Walton, M.R.Edwards, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.
133. N.Glanville, G.R.McLean, B.Guy, et al. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. PLoS Pathog. 2013;9(9):e1003669.• Glanville et al 2013. Immunized mice with RV VP0 (VP4+VP2 precursor capsid protein) and demonstrated production of cross-serotype cellular immune responses and neutralising antibody, evidence supporting further research into a RV vaccine.